INTRODUCTION
The complex between blood-coagulation Factor VIII and von Willebrand Factor (vWF) serves an essential role in the haemostatic process [1] . Factor VIII functions as a cofactor in the activation of Factor X in the intrinsic coagulation pathway [2] [3] [4] . The single polypeptide chain of Mr 260000 [5, 6] is susceptible to limited proteolysis, and consequently circulates as heterodimers of a Cterminal light chain (Mr 80000) and variable derivatives (Mr 50000-180000) of the N-terminal heavy chain [7-91. The persistence of Factor VIII in the circulation is strongly dependent on complex-formation with vWF [1, 10, 11] . vWF circulates in plasma as a heterogeneous population of multimerized dimeric forms [1, 12] . These dimers are composed of monomeric subunits of Mr 250000 that are disulphide-linked in their C-terminal regions; disulphide linkage between the free N-termini then results in multimerization [1, 13] . A minor proportion of the vWF subunits in the multimers contains an uncleaved N-terminal pro-sequence of Mr 100000 [1, 14] .
The nature of the interaction between vWF andFactor VIII is poorly documented. On vWF, a major Factor VIII-binding domain has been located within amino acid residues 1-272 of the mature subunit [15] . The Factor VIII light chain has been shown to be involved in vWF binding [16] . In the present study we describe a method for studying the Fig. 1 ).
Monoclonal antibodies
Mouse monoclonal antibodies against human Factor VIII were produced and purified as described previously [18] . The epitope of antibody CLB-CAg 69 was mapped on the same region of the Factor VIII light chain (amino acid residues 1649-1778) as reported previously for the antibody CLB-CAg 65 [19] . The control antibody CLBCAg 9 recognizes an epitope located between residues 712 and 741 on the heavy chain of Factor VIII [19] . These antibodies do not inhibit Factor VIII activity when tested in the spectrophotometric Factor VIII assay (see below). Micro-titre wells (Immulon; Dynatech G.m.b.H., Plockingen, Germany) were coated with vWF, as follows: various amounts (0-50 munits) of purified human vWF were incubated in 150 mM-NaCl/50 mM-Tris/HCl buffer, pH 7.4 (100 ,u/well), for 2 h at 37 'C. The wells were washed once with 250 mM-CaCl2/150 mM-NaCl/50 mMTris/HCl buffer, pH 7.4, to eliminate any traces of Factor VIII, and twice with the same buffer without CaCl2. Subsequently, the wells were incubated with, per well, 100 ,ul of 20 Fig. 1 ) demonstrated that this rapid washing procedure (less than 5 s) did not disturb the binding equilibrium. Bound Factor VIII was then quantified spectrophotometrically (see below), with the purified Factor VIII preparation as reference.
Quantification of proteins
Concentrations of total protein were determined by the method of Bradford [21] . vWF antigen was quantified as described previously [22] . Factor VIII light chain was measured by using an enzyme-linked immunosorbent assay based on a previously described method [17] . Factor VIII activity was determined spectrophotometrically, by using a method employing a chromogenic substrate and purified bovine coagulation factors (Coatest Factor VIII; KabiVitrum, Stockholm, Sweden). The assay was performed in micro-titre wells essentially as prescribed by the manufacturer. Factor VIII and vWF concentrations are expressed in units/ml; this represents the concentration of activity or antigen in 1 ml of pooled normal human plasma. One unit of Factor VIII and
RESULTS AND DISCUSSION
In the present paper we describe a method for studying the interaction between Factor VIII and vWF. The assay system differs from previously described methods also employing imobilized vWF [16, 23, 24] in that bound Factor VIII is quantified by its biological activity by using a spectrophotometric assay. This approach is based on the notion that the presence of vWF has no effect on the cofactor function of activated Factor VIII [3, 25] [1] . Reversibility of binding was further studied with dissociation experiments in the absence and in the presence of multimeric vWF in solution (Fig. 1) In order to identify the sites involved in the highaffinity Factor VIII-vWF interaction, competition studies were performed with several monoclonal antibodies against Factor VIII. One antibody against plasma Factor VIII, coded CLB-CAg 69, was found to interfere in the Factor VIII-vWF interaction (Fig. 3a) . Similarly, vWF was an effective inhibitor of the binding of Factor VIII to the immobilized antibody (Fig. 3b) . This indicates that the epitope of this antibody may be involved in vWF binding. Previous studies have demonstrated that the epitope of the antibody CLB-CAg 69 is located between amino acid residues 1648 and 1779 in Factor VIII [19] . Pilot experiments (results not shown) using immunoblotting of purified Factor VIII have indicated that antibody CLB-CAg 69 recognizes the Factor VIII light chain (residues 1649-2332; see Fig. 4 ), but not the cleavage product (residues 1690-2332) that is obtained after thrombin digestion. This provided indirect evidence that the sequence at residues 1649-1689, which represents a remarkably acidic region in Factor VIII [5] , contains at least part of the epitope of the antibody that interferes with vWF binding. In agreement with this hypothesis, the antibody was found to recognize a synthetic peptide representing the sequence Lys1673-Arg1689 (see Fig. 4 ).
During the course of our investigations, similar findings were reported by Foster et al. [23] , who described that the Factor VIII-vWF binding could be blocked by an antibody against plasma Factor VIII recognizing an epitope on a synthetic peptide representing the sequence Val16701-Glu1684, whereas antibodies directed against adjoining sequences did not affect vWF binding. The partial overlap between the Val1670-Glu1684 sequence and that of our peptide (see Fig. 4 [7] . The bottom shows the acidic region of the light chain; the bar indicates the synthetic peptide containing the epitope of the monoclonal antibody CLB-CAg 69 that inhibits vWF binding.
involved in vWF binding is located within the sequence Lys673-Glu 684. Since all antibodies known so far to recognize this specific Factor VIII sequence appear to interfere in vWF binding, it seems likely that this site is directly involved in the Factor VIII-vWF interaction. This would be in agreement with recent observations that the presence of the 41-residue acidic region in the light chain is required for vWF binding [26] . Competition experiments demonstrated that the peptide Lys1673-Arg1689 effectively inhibits the binding of the antibody CLB-CAg 69 to Factor VIII: at a peptide concentration of 1 nm, more than 90 % inhibition occurred under the conditions of Fig. 3(b) . In contrast, no inhibition of the Factor VIII-vWF interaction was found with peptide concentrations up to 0.5 /M. An explanation for this finding may be that the synthetic peptide does not reflect the complete vWF-binding site. In this regard, it may be noted that this sequence contains a tyrosine residue (Tyr1680) that is sulphated as a post-translational modification of the Factor VIII protein [27] . Sulphation of the Tyr1680 residue may be essential for vWF binding.
With regard to the stoichiometry within the Factor VIII-vWF complex, it is of interest to know the precise localization of the sites of interaction. In contrast with the site on Factor VIII, the binding site on vWF has not been characterized in detail. This Factor VIII-binding site has recently been assigned to the N-terminal 272 amino acid residues of the mature vWF subunit [15] ..If this site is accessible on all subunits of multimeric vWF, a 1:1 stoichiometry of Factor VIII-vWF binding would be conceivable. Indeed, 1: 1 binding has been observed in sedimentation-velocity studies for the pig proteins [28] . However, it is not evident from such studies whether or no the known heterogeneity of vWF introduces multiple binding affinities. For [29] , a value that approximates the Factor VIII/vWF ratio in human plasma [1] . In our studies the high-affinity interaction was restricted to about 1-20 of the subunits of the vWF multimers. The apparent existence of additional binding sites with lower affinity may be explained by heterogeneity in exposition of the Factor VIII-binding site. One factor that may exert a steric effect is the presence of the vWF propeptide, which is adjacent to the Factor VIII-binding domain, and can be detected on a few per cent of the subunits of vWF multimers secreted by endothelial cells [1, 14] . Alternatively, multimerization (cf. Fig. 1 inset) , which involves cysteine residues located close to the Factor VIII-binding region [13, 15] , may affect Factor VIII-binding affinity. Further studies will be needed to assess whether or not Factor VIII-binding sites on the free termini differ from those within the vWF multimeric chains.
